Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
- PMID:17604802
- DOI: 10.1016/S0140-6736(07)61016-2
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
Abstract
Meningococcus, an obligate human bacterial pathogen, remains a worldwide and devastating cause of epidemic meningitis and sepsis. However, advances have been made in our understanding of meningococcal biology and pathogenesis, global epidemiology, transmission and carriage, host susceptibility, pathophysiology, and clinical presentations. Approaches to diagnosis, treatment, and chemoprophylaxis are now in use on the basis of these advances. Importantly, the next generation of meningococcal conjugate vaccines for serogroups A, C, Y, W-135, and broadly effective serogroup B vaccines are on the horizon, which could eliminate the organism as a major threat to human health in industrialised countries in the next decade. The crucial challenge will be effective introduction of new meningococcal vaccines into developing countries, especially in sub-Saharan Africa, where they are urgently needed.
Similar articles
- Conquering the meningococcus.Stephens DS.Stephens DS.FEMS Microbiol Rev. 2007 Jan;31(1):3-14. doi: 10.1111/j.1574-6976.2006.00051.x.FEMS Microbiol Rev. 2007.PMID:17233633Review.
- Serogroup B meningococcal vaccines.Zimmer SM, Stephens DS.Zimmer SM, et al.Curr Opin Investig Drugs. 2006 Aug;7(8):733-9.Curr Opin Investig Drugs. 2006.PMID:16955685Review.
- The epidemiology of meningococcal disease and the impact of vaccines.Khatami A, Pollard AJ.Khatami A, et al.Expert Rev Vaccines. 2010 Mar;9(3):285-98. doi: 10.1586/erv.10.3.Expert Rev Vaccines. 2010.PMID:20218857Review.
- The implications of vaccines for prevention of bacterial meningitis.Riordan A.Riordan A.Curr Opin Neurol. 2010 Jun;23(3):319-24. doi: 10.1097/WCO.0b013e3283381751.Curr Opin Neurol. 2010.PMID:20173637Review.
- Toward a meningitis-free world.Black S, Pizza M, Nissum M, Rappuoli R.Black S, et al.Sci Transl Med. 2012 Feb 29;4(123):123ps5. doi: 10.1126/scitranslmed.3003859.Sci Transl Med. 2012.PMID:22378923
Cited by
- Cloning, expression, purification and crystallization of an endotoxin-biosynthesis enzyme from Neisseria meningitidis.Anandan A, Piek S, Kahler CM, Vrielink A.Anandan A, et al.Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Dec 1;68(Pt 12):1494-7. doi: 10.1107/S1744309112042236. Epub 2012 Nov 14.Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012.PMID:23192031Free PMC article.
- Can we, should we, eradicate the meningococcus?Maiden MC, Frosch M.Maiden MC, et al.Vaccine. 2012 May 30;30 Suppl 2(6):B52-6. doi: 10.1016/j.vaccine.2011.12.068.Vaccine. 2012.PMID:22607899Free PMC article.Review.
- Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FV, Medah I, Jackson ML.Tartof S, et al.PLoS One. 2013 May 9;8(5):e63605. doi: 10.1371/journal.pone.0063605. Print 2013.PLoS One. 2013.PMID:23671685Free PMC article.
- Molecular characterization of invasive Neisseria meningitidis strains isolated in Chile during 2010-2011.Barra GN, Araya PA, Fernandez JO, Gabastou JM, Hormazábal JC, Seoane M, Pidal PC, Valenzuela MT, Ibarz-Pavón AB.Barra GN, et al.PLoS One. 2013 Jun 11;8(6):e66006. doi: 10.1371/journal.pone.0066006. Print 2013.PLoS One. 2013.PMID:23776590Free PMC article.
- Usefulness of inflammatory biomarkers in discriminating between bacterial and aseptic meningitis in hospitalized children from a population with low vaccination coverage.Gowin E, Wysocki J, Avonts D, Januszkiewicz-Lewandowska D, Michalak M.Gowin E, et al.Arch Med Sci. 2016 Apr 1;12(2):408-14. doi: 10.5114/aoms.2016.59269. Epub 2016 Apr 11.Arch Med Sci. 2016.PMID:27186188Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical